Kennedy Capital Management, Inc. Black Diamond Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.15 Billion
- Q3 2025
A detailed history of Kennedy Capital Management, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 129,944 shares of BDTX stock, worth $547,064. This represents 0.01% of its overall portfolio holdings.
Number of Shares
129,944
Previous 65,875
97.26%
Holding current value
$547,064
Previous $163,000
193.87%
% of portfolio
0.01%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BDTX
# of Institutions
97Shares Held
41.5MCall Options Held
68.7KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$45.2 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.55MShares$23.4 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.7 Million1.03% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$9.22 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $153M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...